Aptevo Therapeutics Inc.
APVO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001671584
No open-market purchases or sales by Aptevo Therapeutics Inc. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $224.3K in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Aptevo Therapeutics Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 26 | 23 | −3 |
| Shares | 2.73M | 760.9K | −1.96M (−72.1%) |
| Value | $42.1M | $5.99M | −$36.1M (−85.8%) |
New holders (5)
Institutions that held Aptevo Therapeutics Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Schonfeld Strategic Advisors LLC | 156,700 | $1.23M | 0.01% |
| Price T Rowe Associates Inc | 46,200 | $364.0K | 0.00% |
| UBS Group AG | 3,212 | $25.0K | 0.00% |
| ACT Capital Management, LLC | 1,500 | $12.0K | 0.01% |
| Total Clarity Wealth Management, Inc. | 500 | $4.00K | 0.00% |
Sold out (8)
Institutions that held Aptevo Therapeutics Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Tang Capital Management LLC | 1,760,000 | $27.2M |
| RTW Investments, LP | 281,402 | $4.34M |
| Towercrest Capital Management | 211,227 | $3.26M |
| Boothbay Fund Management, LLC | 15,350 | $237.0K |
| Gsa Capital Partners LLP | 13,651 | $211.0K |
| JBF Capital, Inc. | 3,907 | $60.0K |
| Tower Research Capital LLC (TRC) | 1,194 | $18.0K |
| IFP Advisors, Inc | 218 | $3.00K |